Page last updated: 2024-08-23

preclamol and Idiopathic Parkinson Disease

preclamol has been researched along with Idiopathic Parkinson Disease in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Antonio, T; Das, B; Dutta, AK; Luo, D; Reith, ME; Vedachalam, S	1
Bravi, D; Chase, TN; Hoff, JI; Metman, LV; Mouradian, MM; Roberts, JR; Sethy, VH	1
Carlsson, A; Merello, M; Pirtosek, Z; Stern, G	2

Reviews

1 review(s) available for preclamol and Idiopathic Parkinson Disease

Article	Year
Preclamol. A "designer drug" in the treatment of advanced Parkinson's disease. Advances in neurology, 1996, Volume: 69 Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Parkinson Disease; Piperidines	1996

Trials

2 trial(s) available for preclamol and Idiopathic Parkinson Disease

Article	Year
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:5 Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Piperidines	1994
Preclamol and parkinsonian fluctuations. Clinical neuropharmacology, 1993, Volume: 16, Issue:6 Topics: Antiparkinson Agents; Apomorphine; Blood Pressure; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement; Parkinson Disease; Piperidines; Receptors, Dopamine D1; Receptors, Dopamine D2	1993

Article

Year

Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:5

Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intramuscular; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Piperidines

1994

Preclamol and parkinsonian fluctuations.

Clinical neuropharmacology, 1993, Volume: 16, Issue:6

Topics: Antiparkinson Agents; Apomorphine; Blood Pressure; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movement; Parkinson Disease; Piperidines; Receptors, Dopamine D1; Receptors, Dopamine D2

1993

Other Studies

1 other study(ies) available for preclamol and Idiopathic Parkinson Disease

Article	Year
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat Journal of medicinal chemistry, 2015, Dec-10, Volume: 58, Issue:23 Topics: Animals; Antiparkinson Agents; Benzothiazoles; Cell Line; Drug Discovery; Female; Humans; Locomotion; Male; Neuroprotective Agents; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship	2015

Article

Year

Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat

Journal of medicinal chemistry, 2015, Dec-10, Volume: 58, Issue:23

Topics: Animals; Antiparkinson Agents; Benzothiazoles; Cell Line; Drug Discovery; Female; Humans; Locomotion; Male; Neuroprotective Agents; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship

2015